Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

P53 Downregulation-Based Strategy to Protect Genomic Integrity from Radiation Therapy

Hang Su, Mei-Jun Long, MD PhD, Joel E Michalek, PhD, Michael Weil, PhD, Chul S Ha, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-139137

Published: 2020

Journal Articles

Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis

Chul S. Ha, MD, Hongli Li, MS, Heiko Schoder, MD, Chelsea C Pinnix, MD, Elizabeth Brem, MD, Nancy L. Bartlett, MD, Andrew M. Evens, DO, MSc, Eric D. Hsi, MD, Lisa M. Rimsza, MD, John P. Leonard, MD, Brad S Kahl, MD, Michael L. Leblanc, PhD, Sonali M. Smith, MD, Louis S. Constine, MD, Jonathan W. Friedberg, MD

Blood (2018) 132 (Supplement 1): 2927.

https://doi.org/10.1182/blood-2018-99-113133

Published: 2018

Journal Articles

Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60

Farhad Ravandi, MD, Megan Othus, PhD, Susan O'Brien, MD, Stephen J. Forman, MD, Chul S. Ha, MD, Jeffrey Y. C. Wong, MD, Martin S Tallman, MD, Elisabeth Paietta, PhD, Janis Racevskis, PhD, Geoffrey L. Uy, MD, Uma Borate, MD, Partow Kebriaei, MD, Laura Kingsbury, MRT, Hagop M. Kantarjian, MD, Jerald P. Radich, Harry P. Erba, MD PhD, Frederick R. Appelbaum, MD

Blood (2015) 126 (23): 796.

https://doi.org/10.1182/blood.V126.23.796.796

Published: 2015

Journal Articles

P53 Based Strategy to Reduce Hematological Toxicity of Chemotherapy: Emerging Support from a Phase II Trial

Chul S. Ha, MD, Joel Michalek, PhD, Richard Elledge, MD, Kevin R. Kelly, MD, PhD, Suthakar Ganapathy, PhD, Hang Su, PhD, Carol Jenkins, RN, BSN, Athanassios Argiris, MD, Ronan Swords, MD, PhD, Tony Y. Eng, MD, Anand Karnad, MD, Richard Crownover, MD, PhD, Gregory P Swanson, MD, Martin Goros, M.S., Brad H Pollock, MPH, PhD, Zhi-Min Yuan, MD, PhD

Blood (2014) 124 (21): 4809.

https://doi.org/10.1182/blood.V124.21.4809.4809

Published: 2014

Journal Articles

P53-Based Strategy for Protection of Bone Marrow From Y-90 Ibritumomab Tiuxetan

Hang Su, Ph.D., Suthakar Ganapathy, Ph.D., Zhi-Min Yuan, M.D., Ph.D., Chul S. Ha, M.D.

Blood (2013) 122 (21): 1839.

https://doi.org/10.1182/blood.V122.21.1839.1839

Published: 2013

Journal Articles

A Novel p53-Based Strategy for Protection of Bone Marrow and Gastrointestinal (GI) Track From Total Body Irradiation (TBI)-Induced Damage.

Chul S. Ha, MD, Suthakar Ganapathy, Ph.D., Zhi Min Yuan, M.D., Ph.D.

Blood (2010) 116 (21): 1454.

https://doi.org/10.1182/blood.V116.21.1454.1454

Published: 2010

Journal Articles

Central Nervous System (CNS) Involvement In Pediatric Relapsed Acute Myeloid Leukemia: Results and Lessons From Study Relapsed AML 2001/01

Gertjan Kaspers, Martin Zimmermann, Dirk Reinhardt, Brenda Gibson, Rienk Tamminga, Olga Aleinikova, Hortensia Armendariz, Michael Dworzak, S. Ha, Lisa Hovi, Alexei Maschan, Andre Baruchel, Yves Bertrand, Bassem Razzouk, Carmelo Rizzari, Petr Smisek, Owen Smith, Batia Stark, Ursula Creutzig

Blood (2010) 116 (21): 184.

https://doi.org/10.1182/blood.V116.21.184.184

Published: 2010

Journal Articles

Addition of Liposomal Daunorubicin (DaunoXome®) to FLAG Significantly Improves Treatment Response in Pediatric Relapsed AML: Final Results From the International Randomised Phase III Study Relapsed AML 2001/01.

G.J.L. Kaspers, M. Zimmermann, D. Reinhardt, B. Gibson, R. Tamminga, O. Aleinikova, H. Armendariz, M. Dworzak, S. Ha, L. Hovi, A. Maschan, A. Baruchel, Y. Bertrand, B. Razzouk, C. Rizzari, P. Smisek, O. Smith, B. Stark, U. Creutzig

Blood (2009) 114 (22): 18.

https://doi.org/10.1182/blood.V114.22.18.18

Published: 2009

Journal Articles

Prognostic Significance of Time to Relapse in Pediatric AML: Results from the International Randomised Phase III Study Relapsed AML 2001/01

G.J.L. Kaspers, M. Zimmermann, D. Reinhardt, B. Gibson, R. Tamminga, H. Armendariz, M. Dworzak, S. Ha, L. Hovi, A. Maschan, A. Baruchel, Y. Bertrand, B. Razzouk, C. Rizzari, P. Smisek, O. Smith, B. Stark, U. Creutzig

Blood (2008) 112 (11): 2976.

https://doi.org/10.1182/blood.V112.11.2976.2976

Published: 2008

Journal Articles

Long-Term Continuing Second Complete Remission (CCR2) despite Allogeneic Stem Cell Transplantation in CR1: Results from the International Randomised Phase III Study Pediatric Relapsed AML 2001/01

Blood (2008) 112 (11): 2977.

https://doi.org/10.1182/blood.V112.11.2977.2977

Published: 2008

Journal Articles

Prognostic Significance of Early Treatment Response in Pediatric Relapsed Acute Myeloid Leukemia: Results from the International Study Relapsed AML 2001/01.

Gertjan J. Kaspers, M. Zimmermann, D. Reinhardt, R. Tamminga, B. Gibson, H. Armendariz, M. Dworzak, S. Ha, L. Hovi, A. Maschan, N. Philippe, B. Razzouk, C. Rizzari, P. Smisek, O. Smith, B. Stark, A. Will, U. Creutzig

Blood (2007) 110 (11): 1843.

https://doi.org/10.1182/blood.V110.11.1843.1843

Published: 2007

Journal Articles

Allogeneic Transplantation after an Alemtuzumab-Containing Myeloablative Conditioning Regimen for CD52 Positive Acute Lymphoblastic Leukemia (ALL).

Partow Kebriaei, MD, Rima M. Saliba, PhD, Carrie Ma, Cindy Ippoliti, PharmD, Daniel R. Couriel, MD, Marcos de Lima, MD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD, James L. Gajewski, MD, Chul S. Ha, MD, Richard E. Champlin, MD, Issa F. Khouri, MD

Blood (2005) 106 (11): 1135.

https://doi.org/10.1182/blood.V106.11.1135.1135

Published: 2005

Journal Articles

The Impact of Rituximab in the Development of Acute Graft Versus Host Disease (GVHD) Following Allogeneic Stem Cell Transplantation (SCT) for Acute Lymphoblastic Leukemia (ALL).

Partow Kebriaei, MD, Rima M. Saliba, PhD, Carrie Ma, Cindy Ippoliti, PharmD, Daniel R. Couriel, MD, Marcus de Lima, MD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD, James L. Gajewski, MD, Chul S. Ha, MD, Richard E. Champlin, MD, Issa F. Khouri, MD

Blood (2005) 106 (11): 1803.

https://doi.org/10.1182/blood.V106.11.1803.1803

Published: 2005

Journal Articles

Relapsed Acute Myeloid Leukemia in Children and Adolescents: Interim Results of the International Randomised Phase III Study “Relapsed AML 2001/01”.

Gertjan J. Kaspers, M. Zimmermann, G. Fleischhack, R. Tamminga, B. Gibson, H. Armendariz, M. Dworzak, S. Ha, L. Hovi, A. Maschan, N. Philippe, B. Razzouk, C. Rizzari, P. Smisek, O. Smith, B. Stark, U. Creutzig

Blood (2005) 106 (11): 897.

https://doi.org/10.1182/blood.V106.11.897.897

Published: 2005

Journal Articles

Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma

Deborah A. Thomas, Susan O'Brien, Jorge Cortes, Francis J. Giles, Stefan Faderl, Srdan Verstovsek, Alessandra Ferrajoli, Charles Koller, Miloslav Beran, Sherry Pierce, Chul S. Ha, Fernando Cabanillas, Michael J. Keating, Hagop Kantarjian

Blood (2004) 104 (6): 1624–1630.

https://doi.org/10.1182/blood-2003-12-4428

Published: 2004

Journal Articles

Risk Factors, Treatment, and Outcome of Central Nervous System Recurrence in Adults With Intermediate-Grade and Immunoblastic Lymphoma

Koen van Besien, Chul S. Ha, Sandy Murphy, Peter McLaughlin, Alma Rodriguez, Kamal Amin, Arthur Forman, Jorge Romaguera, Fredrick Hagemeister, Anas Younes, Carlos Bachier, Andreas Sarris, Kathleen S. Sobocinski, James D. Cox, Fernando Cabanillas

Blood (1998) 91 (4): 1178–1184.

https://doi.org/10.1182/blood.V91.4.1178

Published: 1998

NARROW

P53 Downregulation-Based Strategy to Protect Genomic Integrity from Radiation Therapy

Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis

Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60

P53 Based Strategy to Reduce Hematological Toxicity of Chemotherapy: Emerging Support from a Phase II Trial

P53-Based Strategy for Protection of Bone Marrow From Y-90 Ibritumomab Tiuxetan

A Novel p53-Based Strategy for Protection of Bone Marrow and Gastrointestinal (GI) Track From Total Body Irradiation (TBI)-Induced Damage.

Central Nervous System (CNS) Involvement In Pediatric Relapsed Acute Myeloid Leukemia: Results and Lessons From Study Relapsed AML 2001/01

Addition of Liposomal Daunorubicin (DaunoXome®) to FLAG Significantly Improves Treatment Response in Pediatric Relapsed AML: Final Results From the International Randomised Phase III Study Relapsed AML 2001/01.

Prognostic Significance of Time to Relapse in Pediatric AML: Results from the International Randomised Phase III Study Relapsed AML 2001/01

Long-Term Continuing Second Complete Remission (CCR2) despite Allogeneic Stem Cell Transplantation in CR1: Results from the International Randomised Phase III Study Pediatric Relapsed AML 2001/01

Prognostic Significance of Early Treatment Response in Pediatric Relapsed Acute Myeloid Leukemia: Results from the International Study Relapsed AML 2001/01.

Relapsed Acute Myeloid Leukemia in Children and Adolescents: Interim Report of the International Randomised Phase III Study Relapsed AML 2001/01.

Allogeneic Transplantation after an Alemtuzumab-Containing Myeloablative Conditioning Regimen for CD52 Positive Acute Lymphoblastic Leukemia (ALL).

The Impact of Rituximab in the Development of Acute Graft Versus Host Disease (GVHD) Following Allogeneic Stem Cell Transplantation (SCT) for Acute Lymphoblastic Leukemia (ALL).

Relapsed Acute Myeloid Leukemia in Children and Adolescents: Interim Results of the International Randomised Phase III Study “Relapsed AML 2001/01”.

Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma

Risk Factors, Treatment, and Outcome of Central Nervous System Recurrence in Adults With Intermediate-Grade and Immunoblastic Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only